Androstenedione Production and Interconversion Rates
Measured in Peripheral Blood and Studies on the Possible Site of Its Conversion to Testosterone *

R. Horton † and J. F. Tait ‡
(From the Worcester Foundation for Experimental Biology, Shrewsbury, Mass.)

The present aim of in vivo studies of steroid dynamics in the androgen field is to obtain estimates of the total rate of entry of testosterone and its major precursors such as androstenedione into the general circulation, i.e., the blood production rates (1–7). Also required are the secretion rates of this steroid and its precursors, the relative contributions of these secretions to the blood production rates, and a knowledge of the original anatomical sites of these interconversions and secretions.

Previous approaches and solutions to these problems have been questioned because in certain situations, when urinary and blood production rate estimates differ, the total rate of entry of steroid into the general circulation cannot be obtained from urinary studies (6, 7). Also the metabolism of a secreted steroid and the same steroid produced from precursor cannot be regarded as being equivalent (8), which is the basic assumption of one urinary approach (2) and one combined blood and urinary approach (6) used to calculate secretion rates. Presumably, both the production and mode of metabolism of a steroid may vary at different anatomical sites (5, 8–10).

To avoid these difficulties, we have measured production and interconversion rates of testosterone and androstenedione directly in the peripheral circulation. Because the output of steroids from endocrine glands is into the same circulation, the secretion rate is a higher proportion of the blood production compared with the corresponding urinary production rate in situations when the two estimates differ (8). The approach using blood measurements would then be expected to lead to more precise estimates of secretion rates.

Methods

Normal adults, aged 21 to 33, were used in these studies. All female subjects gave histories of normal and regular menstrual cycles, were in excellent general health, and received no medications. Plasma testosterone and androstenedione in plasma were estimated by a double isotope derivative technique using thiosemicarbazide-35S as reagent (11, 12). Ten ml of plasma was obtained from fasting subjects between 8 and 9 a.m. and, after addition of tritiated indicator to allow for losses, was frozen for later assay. Unless otherwise stated, plasma specimens for the subjects in this study were obtained before the start of the continuous infusion used to determine clearance values. This was done to avoid any possible effect of the infusion on plasma concentrations due, for example, to stress of the procedure.

Benzene, toluene, ethyl acetate, and methanol used for the chromatographic systems were spectrograde. Pyridine and acetic anhydride were prepared as described for estimation of testosterone (11). Materials and procedures for the thiosemicarbazide-35S methods were as described elsewhere (11, 12). Propylene glycol and anhydrous ether were used without further purification. The 4H- and 13C-labeled steroids (testosterone-4,14C and androstenedione-4,14C, testosterone-1,2-3H and androstenedione-1,2-3H) were further purified by partition chromatography on Celite in the Bush B-3 system (stationary phase: methanol, water, 4:1; mobile phase: Skellysolve C, benzene, 2:1). Androstenedione-3H and 14C were made by oxidation of testosterone-1,2-3H and 14C with 0.2 ml 0.5% chromium trioxide in 95% acetic acid for 1 hour in the dark, dilution with 1 ml 20% ethanol, and extraction with methylene chloride (spectrograde). The washed extract taken to dryness was then chromatographed on the Celite column.

† American Cancer Society Investigator PF-256.
‡ Recipient of U. S. Public Health Service Research Career Program Award GM-K6-18322.

* Submitted for publication August 30, 1965; accepted November 18, 1965.
This work was supported by U. S. Public Health Service grants AM-08387 and AM-03179.
† Address requests for reprints to Dr. R. Horton, Dept. of Medicine, University of California at Los Angeles, Los Angeles, Calif.
‡ Made by oxidation of testosterone-1,2-3H and 14C with 0.2 ml 0.5% chromium trioxide in 95% acetic acid for 1 hour in the dark, dilution with 1 ml 20% ethanol, and extraction with methylene chloride (spectrograde).
Testosterone and androstenedione carrier steroid ran, in all systems used, as a single compound as detected by absorption of ultraviolet light (254 nm).

**Thin layer chromatography (TLC).** The initial separation from plasma in the clearance rate determination was with alumina* thin layer (300 μ thick) on glass plates with the system benzene, ethyl acetate, 3:1, developed in a single direction. The plate was heated to 100°C for 1 hour and stored in a desiccator before use. This TLC with alumina will separate testosterone from epitestosterone and androstenediol, and androstenedione from androstanediol and etiocholanolone. The capacity of the system allows the use of an ether extract of 50 ml plasma as a 1-cm streak with adequate resolution of these steroids in 2 hours.

**Paper chromatography.** The second chromatography system in the clearance work was a modified Bush A system (stationary phase: methanol, water, 0.85:0.15; mobile phase: Skellysolve C). The system was equilibrated for 5 hours and developed for 12 hours. The carrier steroids were located by their absorption of ultraviolet light (254 nm).

The combination of these two systems separated the two steroids from all expected metabolites.

**Radioactive counting.** All counting was performed with a Nuclear-Chicago liquid scintillation spectrometer, model 725. For the clearance and conversion work the dried samples were rinsed three times with 0.2 ml absolute ethanol and transferred to 10 ml toluene containing 0.4% diphenyloxazole and 0.005% 1,4-bis-2-(5-phenyl-oxazolyl) benzene. Discrimination and gain settings were such to give an efficiency of 40% for 14C (H then 0.1%) and 12% for 3H (14C then 15%) with backgrounds of 7 and 24 cpm, respectively. Samples were counted five times for 40 minutes each and gave a SE of less than 5%.

**Measurement of metabolic clearance rate of androstenedione and testosterone.** A priming dose of 3 μ 1,2-3H-labeled androstanediol or testosterone (0.022 μg, SA 137 μc per μg) was injected intravenously in 10 ml sterile isotonic saline over a 2-minute period to prone, fasting subjects at about 8:30 a.m. One half hour later, a constant continuous infusion of a total of 7 to 10 μc 3H-labeled steroid (0.05 to 0.07 μg) in 50 ml of 8% ethanol in isotonic saline was started with a Harvard infusion pump fitted with a 50-ml Yale infusion syringe. The infusion at a calibrated rate of 0.382 ml per minute was given through a three-way stopcock with 20-inch extension tubing into the left median basilic vein through a size 21 needle. Whole blood (50 ml) was drawn into heparinized disposable plastic syringes from the right arm at 85, 100, and 115 minutes after the start of the infusion. Samples of the infusion solution were obtained both from the syringe and from the tubing. The blood was immediately centrifuged and the plasma removed and cooled with ice in 50-ml measuring cylinders. Fifty μg carrier steroid, 14C indicator (180 to 200 cpm) in 0.2 ml ethanol, and 2 ml 3 N NaOH were mixed with the plasma in a 125-ml separatory funnel and the steroids extracted twice with 2 vol cold ether. The ether was then washed twice with 10 vol H₂O and the extract dried in vacuo and spotted on the alumina thin layer plate. After running in this system in one dimension, the carrier steroids were located under a 254-nm ultraviolet lamp, marked, and aspirated under low vacuum into a pipette packed with glass wool. The inverted pipette was then eluted with 10 ml ethanol and the eluate taken to dryness. This extract was next streaked over a 2-cm line on Whatman 2 paper and run in the Bush A system for 12 hours. The area was then cut out and eluted with 10 ml ethanol with a 15-ml syringe fitted with a 25-gauge needle (R₇ testosterone 0.3, androstenedione 0.5). The dried extract was transferred to counting vials. The metabolic clearance rate by constant infusion was calculated as the rate of radioactive infusion divided by the plasma radioactivity per liter corrected for recovery and measured specifically as the same steroid as that infused (13).

**Conversion rate determination in blood.** The conversion rates in blood were performed as part of the continuous infusion clearance rate determinations. To the plasma specimens, carrier and 14C indicator of the product steroid were also added (i.e., after infusion of androstenedione-3H, addition of both 14C and carrier androstenedione and testosterone). The product steroid was also isolated from plasma by the TLC and paper systems. This procedure was usually carried out for the last two plasma samples (Table I) and the mean value taken for further calculations. The conversion factor in plasma was calculated as ratio of product to precursor in counts per minute per liter all corrected for recovery \( \frac{\text{Rx}}{\text{Rx} + \text{Rx}} \) after infusion of radioactive androstenedione (Rx) and \( \frac{2\text{H}}{2\text{H}} \) after radioactive testosterone (Rx).

**Hepatic extraction of testosterone produced in the liver.** Androstenedione-14C (total 4 μc, for 2 hours) prepared in a similar manner to the titrated steroid was administered by continuous infusion through a 30-cm Tygon tube placed into a nasogastric tube (size 12 French) inserted into the lower stomach. Plasma specimens were handled as for the routine clearance and inter-conversion rate studies in two experiments. However, in one male and one female subject, testosterone-4H (total 10 μc, for 2 hours) was also infused simultaneously with the gastric infusion but into the left basal vein. In these experiments, the 14C/4H ratios of testosterone in plasma and of the testosterone released from urinary testosterone glucuronide were determined and compared with one another and also with the 3H/14C ratio of the infused material (androstenedione-14C and testosterone-4H infused in the same time interval). For both urine and blood, carrier steroid but not radioactive indicators was added for these two experiments. Urine was collected for 48 hours, pooled, and a \( \frac{12}{12} \) aliquot of the total analyzed in duplicate. The urine, after two preliminary extractions with 1 vol methylene chloride, was adjusted to pH 4.6 with potassium acetate-acetic acid buffer and incubated with 500 U per ml β-glucuronidase (Ketodase) at 37°C for 24 hours in a stoppered flask. The urine was then

---

* Neutral alumina, E. Merck GF 254, distributed by Brinkmann Instruments, Great Neck, N. Y.
cooled with ice water and extracted twice with 1.5 vol ether with added 60 μg carrier testosterone. The ether extract was washed twice with 5% vol 1 N NaOH and twice with 1% vol H₂O. The dried extract was then chromatographed in the alumina thin layer system then on paper in the Bush A system as described for the plasma separation. The dried eluate from paper was then reacted overnight at room temperature in the dark with 0.3 ml pyridine and 0.15 ml acetic anhydride. One-tenth ml ethanol fastened drying under vacuum, and the extract was rechromatographed for 4 hours with parallel running testosterone acetate in the A system. The eluate from the area corresponding to the acetylated steroid was transferred to counting vials as described above and the isotope ratio determined. Total urinary excretion was determined by counting 0.3-ml portions of urine and all samples and standards in a scintillation fluid consisting of 0.3 ml urine, 6 ml ethanol, and 10 ml toluene. The toluene contained 0.4% diphenyloxazole and 0.005% 1,4-bis-2-(5-phenyloxazolyl) benzene. The settings were altered on the scintillation counter to the balance point for ³H counting in this mixture.

**Evidence for radiochemical purity of the labeled steroids infused.** The labeled steroids were all chromatographed on a (30-g, 15-ml stationary phase) Celite column with either the Bush A or Bush B3 system taking only two 5-ml peak fractions. Evidence for purity is dependent upon the demonstration of constancy of the ³H/³C ratio after addition of ³C-labeled steroid initially and of samples taken after alumina TLC and paper chromatography (e.g., initial androstenedione ratio after column, 16.9: ratio after TLC, 16.8; and after paper chromatography, 16.8).

**Evidence for radiochemical purity of labeled androstenedione and testosterone isolated from plasma during continuous infusion.** In this study, all three plasma samples obtained from an infusion were pooled (75 ml) and ³C indicator and carrier of the infused steroid added, and after the TLC and Bush A paper chromatography, one-third was taken for counting. The remaining extract was dried under vacuum and for androstenedione was reacted with 1 mg thiosemicarbazide in 0.5 ml methanol and 0.05 ml glacial acetic acid overnight at 48°C in a 25-ml round-bottom stoppered flask. The androstenedione 3,17-bisthiosemicarbazone derivative with 20 μg carrier was extracted twice, after addition of 1 ml aqueous 5.9% sodium carbonate with methylene chloride, 6 ml, and the dried extract run for 24 hours in a 20% toluene-propylene

### Table I

**Data for the determination of MCRA, MCR₇, x₄/x₇, and x₇/x₄**

<table>
<thead>
<tr>
<th>Subject</th>
<th>Sex</th>
<th>Cpm/day infused androstenedione-H²</th>
<th>Cpm/L plasma androstenedione (&lt;x₄&gt;) after priming dose</th>
<th>Cpm/L plasma testosterone (&lt;x₇&gt;) after priming dose</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>115 min 130 min 145 min Mean</td>
<td>L/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>130 min 145 min Mean x₇/x₄ [x₇]x₄¹⁺²</td>
</tr>
<tr>
<td>1. K.R.</td>
<td>M</td>
<td>5.76 x 10⁴</td>
<td>2,020</td>
<td>2,850</td>
</tr>
<tr>
<td>2. M.M.</td>
<td>M</td>
<td>11.3 x 10⁴</td>
<td>4,800 5,050 5,100 5,000</td>
<td>2,260</td>
</tr>
<tr>
<td>3. R.H.</td>
<td>M</td>
<td>11.0 x 10⁴</td>
<td>4,300 4,600 4,480 4,460</td>
<td>2,470</td>
</tr>
<tr>
<td>4. C.P.</td>
<td>M</td>
<td>16.6 x 10⁴</td>
<td>7,500 7,450 7,550 7,550</td>
<td>2,220</td>
</tr>
<tr>
<td>5. N.G.</td>
<td>M</td>
<td>15.1 x 10⁴</td>
<td>5,100 5,470 5,220 5,260</td>
<td>2,860</td>
</tr>
<tr>
<td>6. G.M.</td>
<td>M</td>
<td>14.75 x 10⁴</td>
<td>7,200 7,000 7,500 7,700</td>
<td>1,920</td>
</tr>
<tr>
<td>7. L.M.</td>
<td>F</td>
<td>5.93 x 10⁴</td>
<td>2,060 1,980 2,020 2,020</td>
<td>2,040</td>
</tr>
<tr>
<td>8. D.B.</td>
<td>F</td>
<td>12.25 x 10⁴</td>
<td>6,520 5,850 5,670 6,010</td>
<td>2,037</td>
</tr>
<tr>
<td>9. J.F.</td>
<td>F</td>
<td>17.3 x 10⁴</td>
<td>8,000 7,900 8,100 8,000</td>
<td>2,160</td>
</tr>
<tr>
<td>10. P.N.</td>
<td>F</td>
<td>16.25 x 10⁴</td>
<td>7,380 7,380 7,600 7,470</td>
<td>2,220</td>
</tr>
<tr>
<td>11. J.R.</td>
<td>F</td>
<td>15.5 x 10⁴</td>
<td>9,050 8,460 8,400 8,630</td>
<td>1,800</td>
</tr>
<tr>
<td>12. D.B.</td>
<td>F</td>
<td>22.1 x 10⁴</td>
<td>9,810</td>
<td>2,250</td>
</tr>
</tbody>
</table>

**Mean ± SE**

<table>
<thead>
<tr>
<th>Cpm/day infused testosterone-H²</th>
<th>Cpm/L plasma testosterone (&lt;x₇&gt;) after priming dose</th>
<th>Cpm/L plasma androstenedione (&lt;x₄&gt;) after priming dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. N.G.</td>
<td>M</td>
<td>24.2 x 10⁴</td>
</tr>
<tr>
<td>2. M.M.</td>
<td>M</td>
<td>25.3 x 10⁴</td>
</tr>
<tr>
<td>3. C.P.</td>
<td>M</td>
<td>41.4 x 10⁴</td>
</tr>
<tr>
<td>4. L.N.</td>
<td>F</td>
<td>34.2 x 10⁴</td>
</tr>
<tr>
<td>5. J.F.</td>
<td>F</td>
<td>26.2 x 10⁴</td>
</tr>
</tbody>
</table>

**Mean ± SE**

1. Sample obtained from tubing during infusion.
2. MCRA and MCR₇ = metabolic clearance rate of androstenedione and testosterone.
3. (x₇)x₄ and (x₇)x₄ calculated as (MCRA/MCR₇) x (x₇/x₄) and (MCRA/MCR₇) x (x₇/x₄) taking MCR₇ = 980 L per day (mean continuous infusion and single injection data (5)). MCRA = 2,380 L per day.

### Footnotes

* MCRA and MCR₇ = metabolic clearance rate of androstenedione and testosterone.

**Evidence for radiochemical purity of labeled androstenedione and testosterone isolated from plasma during continuous infusion.** In this study, all three plasma samples obtained from an infusion were pooled (75 ml) and ³C indicator and carrier of the infused steroid added, and after the TLC and Bush A paper chromatography, one-third was taken for counting. The remaining extract was dried under vacuum and for androstenedione was reacted with 1 mg thiosemicarbazide in 0.5 ml methanol and 0.05 ml glacial acetic acid overnight at 48°C in a 25-ml round-bottom stoppered flask. The androstenedione 3,17-bisthiosemicarbazone derivative with 20 μg carrier was extracted twice, after addition of 1 ml aqueous 5.9% sodium carbonate with methylene chloride, 6 ml, and the dried extract run for 24 hours in a 20% toluene-propylene
glycol system. For testosterone in a similar study, after the Bush A chromatography, the extract was acetylated with pyridine and acetic anhydride and the dried extract rechromatographed in the Bush A system for 4 hours (Rf 0.8, testosterone acetate). In both studies the isotope ratios after further derivative formation were unchanged within the limits of counting error (± 2%). The ratio \(^{1}H/^{13}C\) of androstenedione after the Bush A was 2.41, as the thiosemicarbazone 2.36; the ratio \(^{1}H/^{12}C\) of testosterone after the Bush A was 14.7, as acetate 14.4.

**Evidence for radiochemical purity of testosterone-\(^{4}H\) and androstenedione-\(^{4}H\) obtained in plasma from precursor steroid.** After continuous infusion of androstenedione-\(^{4}H\), a pool of the plasma samples obtained with added testosterone-\(^{12}C\) and carrier testosterone was carried through the TLC and paper systems. Again a sample was taken for counting, the remainder acetylated, and the testosterone acetate rerun in the Bush A system. The \(^{12}C/^{1}H\) ratio of the product was essentially unchanged after derivative formation (\(^{13}C/^{1}H\) ratio 4.38 after routine separation and 4.44 after acetylation and further chromatography). The conversion rate in this female subject was 15%, which was about the normal mean value.

Evidence for the radiochemical purity of androstenedione-\(^{4}H\) after infusion of testosterone-\(^{4}H\) was difficult to demonstrate, since the conversion rate was in all cases less than 3%. Although the resultant radioactivity was sufficient for reasonably accurate interconversion measurements, after paper chromatography it was so low as to preclude further extensive study particularly since the formation of the thiosemicarbazone derivative and further chromatography gave low recoveries. Evidence for radiochemical isolation for this conversion rests on the almost identical \(^{13}C/^{1}H\) ratio obtained after the alumina TLC and the subsequent Bush A paper chromatography (7.0 and 7.2, 2% statistical counting error) in the investigation of one pooled sample after infusion of radioactive testosterone. The interconversion rate was about equal to the normal mean in this subject.

**Evidence that equilibrium in plasma was attained during the continuous infusion.** Analysis of radioactivity as the purified \(^{4}H\)-labeled steroid (same as infused steroid) corrected for recovery from the three plasma specimens obtained at 115, 130, and 145 minutes after the priming dose does not indicate a trend in values. If the value at 130 minutes is taken as comparison, the mean value at 115 minutes was 100 ± 2 (SE) and at 145 minutes 99 ± 1% (SE) for the androstenedione radioactivity after androstenedione-\(^{4}H\) infusion and 108 ± 7 (SE) at 115 minutes and 102 ± 3% (SE) at 145 minutes for testosterone radioactivity after testosterone infusion. Both these analyses showed no significant trend in values.

The mean deviation of the product steroids, testosterone-\(^{4}H\) and androstenedione-\(^{4}H\), of the individual values at 130 minutes and 145 minutes from their mean was 5%, maximum 14% and 2%, maximum 3% (Table I). In two experiments when the radioactivity as the product in all three plasma samples (115, 130, and 145 minutes after the priming dose) was measured, there was no significant trend in the values.

**Indication that high specific activity nonpolar C-19 steroids can adsorb to glass and plastic tubing.** Initial evidence was obtained that high specific activity \(^{4}H\)-labeled steroid diluted with isotonic saline could be significantly adsorbed to the glass of an infusion syringe over a 2-hour period. This was particularly true for the more nonpolar androstenedione-\(^{2}H\). This difficulty was eliminated by increasing the solubility of the steroid in the infusion solution by using 8% ethanol in sterile isotonic saline. However, for androstenedione there was still the problem of adsorption to the sterile polyethylene tubing, which with low infusion rates could be significant (12 to 16%). This effect was not completely eliminated, but with a constant infusion the delivery of labeled steroids from the tubing was found to be unchanged throughout the infusion, and sampler could be removed from the tubing for counting and the true infusion rate of labeled steroid into the subject calculated. This latter difficulty was insignificant for the more polar testosterone.

Recent experience has indicated in the nasogastric infusion study that Teflon tubing will not adsorb to any degree either steroid, and so Teflon tubing was used as an inner lining to the usual nasogastric tube.

**Conversion of androstenedione to testosterone after withdrawal of blood.** Fifty ml whole blood freshly drawn into heparinized syringes was incubated for 1 hour at room temperature with androstenedione-\(^{4}H\). After centrifugation, the plasma with testosterone-\(^{12}C\) indicator and carrier was processed as for the study of metabolic clearance rate. Background counts were obtained in the testosterone fraction, indicating the absence of conversion by whole blood itself or the alumina or paper chromatographic systems employed in these studies.

**Results.**

**Metabolic clearance rate.** The metabolic clearance rates of androstenedione (MCR\(^{A}\)) by continuous infusion were 2,430 ± 150 (SE) L per day (6 subjects) in the male and 2,230 ± 190 (SE) L per day (6 subjects) in the female. There was no significant difference in values in both sexes, and the combined values were 2,330 ± 107 (SE) L per day (12 subjects) (Table I).

The metabolic clearance rate of testosterone (MCR\(^{B}\)) by continuous infusion was 1,110 L per day in males (3 subjects) and 892 L per day (3 subjects, including one value of 916 L per day not in Table I) in females. When these values were combined with those recently reported by one of the authors (3), the combined male values were 1,018 ± 74 (SE) (8 male subjects) and 894 ± 47 (SE) L per day (5 female subjects), and again there was no significant difference between male
and female values with the number of subjects used, and the combined values were 980 ± 54 (SE) L per day (13 subjects).

**Plasma concentration of androstenedione and testosterone.** The values for androstenedione in plasma were 0.060 ± 0.004 (SE) μg per 100 ml (12 subjects) in males and 0.140 ± 0.008 (SE) μg per 100 ml (16 subjects) in females. These values were corrected for the mean blank value of the method (water and plasma from ovariectomized-adrenalectomized subjects) (12). Testosterone values in the normal male have been reported as 0.80 ± 0.07 (SE) μg per 100 ml plasma (11 subjects) (11) and 0.034 μg ± 0.008 (SE) μg per 100 ml plasma (60 subjects) for females with the thiosemicarbazide-4S method (14). Female values for testosterone in the group studied here were 0.040 ± 0.007 (SE) μg per 100 ml plasma (8 subjects). There was thus no significant difference in values of testosterone in our group and those of Lobotsky, Wyss, Segre, and Lloyd (14), which were obtained by the same method. The mean of both of these groups was therefore taken for the following calculations. Values for androstenedione taken at the beginning of the infusion study, 0.110 μg per 100 ml for the male (6 subjects) and 0.172 μg per 100 ml (4 subjects) in the female, were somewhat higher than those obtained in the basal state. These slightly higher values might be the result of the anticipated stress of the procedure, which has also been shown to elevate progesterone in plasma (15). These elevated values have not been included in the following calculations.

**Production rate in blood.** The production rate in blood was calculated as the product of metabolic clearance rate (MCR and MCR4) and plasma concentration (iA and iA4) (16). The production rate in blood is therefore 3.4 mg per day in the female and 1.4 mg per day in the male for androstenedione and 0.34 mg per day for the female and 7.8 mg per day for the male for testosterone.

**Conversion ratios in blood.** The conversion ratios, CBBAT and CBBTA, are calculated as the ratio of counts per minute per liter of plasma of product to precursor, both corrected for recovery after infusion of precursor. The subscript letters on the symbol refer to infusion and measurement in blood, the superscript to the infused and measured steroid. The conversion ratio of androstenedione/testosterone (CBBTA = \( z^A/z^T \)) after infusion of testosterone was 2.8 ± 0.2% (SE) (5 subjects). The conversion ratio of testosterone/androstenedione [CBBAT = \( x^T/x^A \) was 14 ± 1% (SE) (12 subjects)]. There was no significant difference between the male 13 ± 2.5% (SE) (6 subjects) and female 14 ± 1% (SE) (6 subjects) conversion ratios (CBBAT) (Table I).

**The contribution of androstenedione in blood to circulating testosterone.** Since the conversion ratio of androstenedione/testosterone after infusion of testosterone (CBBTA) is only 2.8%, the contribution of plasma testosterone to plasma androstenedione in the female (0.035 \( \times \) 0.028 = 0.001 = 0.1%) is insignificant. However, the product of the higher concentration of androstenedione (0.140 μg per 100 ml) and reverse conversion ratio (CATT = 14%) indicates that a significant amount (0.020 μg per 100 ml) of testosterone is derived from blood androstenedione. The actual total concentration of testosterone is 0.035 μg per 100 ml. Thus the ratio 0.020/0.035 μg per 100 ml indicates that 60% of testosterone in the female is derived from androstenedione in blood by peripheral conversion (Figure 1). In the male almost the opposite conclusion can be drawn. The contribution of plasma androstenedione to testosterone (0.060 \( \times \) 0.014) is only 0.002 μg per 100 ml or <0.3% of plasma testosterone. However, due to the very small amount of androstenedione in male plasma in contrast to testosterone, the contribution of plasma testosterone to androstenedione is 0.022 μg per 100 ml (0.80 \( \times \) 0.028) or 36% of plasma androstenedione in the male (Figure 1).
Transfer constants ([ρ] values) measured in blood after intravenous infusion. A transfer constant [ρ]_{BB} for conversion of a precursor to product as measured in the peripheral blood can also be usefully and more generally defined as the fraction of the total amount of precursor entering the blood that enters the same circulation as the product. In this definition the total amount of product entering the blood before metabolism from the same circulation is measured, and the mechanism of the formation and further metabolism are irrelevant, e.g., it may be hepatic or extrahepatic. The [ρ]_{BB}^{AT} value for conversion of androstenedione to testosterone in blood is given by the rate of infusion of radioactive androstenedione (Rx^{A} = plasma radioactive concentration as androstenedione (x^{A}) multiplied by the MCR of androstenedione (MCR^{A})) and the rate of appearance of radioactive testosterone (Rx^{T} = plasma radioactive concentration of testosterone (x^{T}) multiplied by the MCR of testosterone (MCR^{T})).

Therefore,

\[ [\rho]_{BB}^{AT} = \frac{Rx^{T}}{Rx^{A}} = \frac{MCR^{T}}{MCR^{A}} \times \frac{x^{T}}{x^{A}}, \]

and

\[ [\rho]_{BB}^{TA} = \frac{Rz^{A}}{Rz^{T}} = \frac{MCR^{A}}{MCR^{T}} \times \frac{z^{A}}{z^{T}}. \]

From the values previously given,

\[ [\rho]_{BB}^{AT} \approx 980 \times 2,330 \times 14\% = 5.9\%, \]

and

\[ [\rho]_{BB}^{TA} \approx 2,330 \times 980 \times 2.8\% = 6.6\%. \]

Therefore, 5.9% of intravenously infused androstenedione enters the blood as testosterone, and a similar per cent (6.6) of infused testosterone is converted to androstenedione.

The fraction of the blood production rate of testosterone (P_{B}^{T}) coming from the blood production rate of androstenedione (P_{B}^{A}) (but not including precursor originating from the product) is given by the expression (17),

\[ [\rho]_{BB}^{AT} \frac{P_{B}^{A}}{P_{B}^{T}} / 1 - [\rho]_{BB}^{AT} [\rho]_{BB}^{TA}, \]

where [\rho]_{BB}^{AT} P_{B}^{A} is the production of testosterone in the blood arising from the production of androstenedione and [\rho]_{BB}^{AT} P_{B}^{A}/P_{B}^{T} is the fraction of total P_{B}^{T} made in this manner.

A similar expression,

\[ \frac{[\rho]_{BB}^{TA} P_{B}^{T}}{P_{B}^{A}} / 1 - [\rho]_{BB}^{AT} [\rho]_{BB}^{TA}, \]

gives the fraction of the blood production of androstenedione coming from testosterone.

Usually in this type of calculation a correction (1/1 - [\rho]_{BB}^{AT} [\rho]_{BB}^{TA}) has to be made because some of the precursor considered has arisen initially from the product. However, with the values presented here, [\rho]_{BB}^{AT} [\rho]_{BB}^{TA} = 0.059 \times 0.066 \ll 1, and the correction is negligible.

The calculated fractions are the same in value as those already made in terms of plasma concentrations (i^{T} and i^{A}) and (x^{T}/x^{A}) and (z^{A}/z^{T}), as for example,

\[ \frac{[\rho]_{BB}^{AT} P_{B}^{A}}{P_{B}^{T}} = \frac{MCR^{T}}{MCR^{A}} \times \frac{x^{T}}{x^{A}} \times \frac{MCR^{A} \times i^{A}}{MCR^{T} \times i^{T}} \]

\[ = \frac{x^{T}}{x^{A}} \times \frac{i^{A}}{i^{T}} \times \frac{C_{BB}^{AT} \times i^{A}}{i^{T}}. \]

Steroids in blood after oral infusions. An investigation into the site of the conversion of androstenedione to testosterone, e.g., whether this occurs in the splanchnic or extrasplanchnic circulation, requires measurement of the conversion rate in a situation where any possible extrasplanchnic conversion of androstenedione to testosterone is considerably reduced compared with when androstenedione is administered intravenously.

When androstenedione-14C was introduced by continuous infusion into the gastrointestinal tract, the fraction entering the general circulation as androstenedione could be calculated as 14C radioactivity per liter plasma as androstenedione (corrected for losses) \times MCR^{A} divided by rate of infusion of androstenedione-14C. In two experiments, this fraction was 0.103 and 0.023, mean 6.3%, taking MCR^{A} = 2,330 L per day. Therefore, in this situation, only 6.3% \times [\rho]_{BB}^{AT} = 6.3 \times 5.9 = 0.37% of the orally infused androstenedione could appear in the plasma as radioactive testosterone because of extrasplanchnic conversion of androstenedione, whereas after intravenous administration of androstenedione 5.9% could be converted in this manner. If the conversion of oral androstenedione to blood testosterone is not entirely extrasplanchnic, the conversion value will
be even less than 0.37%, and this is a maximal estimate. Efficient absorption by the intestinal tract was shown by the 83 and 88% total urinary recovery of $^{14}C$ in these experiments.

The fraction of orally infused androstenedione that enters the circulation as testosterone is similarly given by the expression, $^{14}C$ radioactivity per liter plasma as testosterone (corrected for losses) $\times$ MCR$^T$ divided by the rate of infusion of androstenedione-$^{14}C$. This fraction was 1.9 and 1.8 in the two experiments (2 males). In two other experiments (1 male, 1 female) testosterone-$^3$H was infused intravenously simultaneously with the oral infusion of androstenedione-$^{14}C$. The fraction of androstenedione in the general circulation as testosterone can then be calculated by the expression (which is equivalent to the one given above), $^{14}C/^3H$ as plasma testosterone $\div ^{14}C/^3H$ of infused steroids in equivalent time interval. The estimates obtained were 1.2 (male) and 2.3 (female), which are in reasonable agreement with those obtained in the first two experiments, which used an MCR$^T$ value from other data. The mean of the four estimates was 1.8%.

As a maximum of 0.37% of the oral androstenedione in plasma as testosterone could arise by extrasplanchnic conversion, as previously calculated, it seems that most of the total conversion of 1.8% originates from testosterone produced in the liver.

In the last two experiments, the $^{14}C/^3H$ ratio of testosterone released from urinary testosterone glucuronide was also measured. The $^{14}C/^3H$ ratio of this urinary testosterone divided by the $^{14}C/^3H$ ratio of the infused material gave values of 100 and 79, mean 89%, from which it can be concluded that the absorption of androstenedione by the intestinal tract and its conversion to testosterone in the liver are highly efficient if testosterone glucuronide is made hepatica. If 89% of the oral androstenedione is converted to testosterone in the liver, then (1.8/0.89) = 2.0% of testosterone produced hepatically must enter the circulation, or the hepatic extraction of testosterone produced in this manner is 98.0%. A more direct calculation can be made from the results of the last two experiments by using the expression, $^{14}C/^3H$ of blood testosterone divided by $^{14}C/^3H$ of urinary testosterone. The values obtained in this manner were 1.2 and 2.3% for steroid entering the circulation as a fraction of the testosterone produced in the liver and 98.8 and 97.7 (mean 98.2%) for hepatic extraction.$^6$

$^6$ The calculation of the conversion of androstenedione, whether administered orally or intravenously, to testosterone in the liver ($[\rho]_{OB}^{AT}$ or $[\rho]_{OL}^{AT}$ values), which is made by comparing the conversion of the oral or intravenous precursor and intravenously administered testosterone to urinary testosterone glucuronide, depends on the following assumptions: 1) Testosterone glucuronide is produced hepatically. This will be discussed in the text. 2) The testosterone is not made extrasplanchnically relative to the amounts made in the splanchnic circulation. As regards the oral administration of androstenedione, the appropriate relative quantities are < 0.4 extrasplanchnic and 89% splanchnic, for intravenous injection 5.9 extrasplanchnic and 40% splanchnic. Therefore, this is a reasonable approximation. 3) Intravenously administered testosterone is not metabolized extrasplanchnically. The low MCR of testosterone indicates that this is probably so, but this assumption remains a possible source of error. 4) The fraction of testosterone made from androstenedione in the liver is converted to testosterone glucuronide to the same extent as testosterone entering the splanchnic circulation from intravenous administration. This assumption is a possible major uncertainty in the calculations of the amount of testosterone produced from androstenedione in the liver.

In the comparison of the conversion of oral and intravenous androstenedione to testosterone in the liver, these four assumptions are involved, but the first two are probably valid. Assumptions 3 and 4 are more uncertain. However, as in both types of experiments the conversion of androstenedione to urinary testosterone glucuronide was compared to that of intravenously administered testosterone, any correction due to the failure of assumptions 3 and 4 will be common to both calculations, and the comparison will be valid.

The calculations of hepatic extraction (H) will be affected by any failure in all four assumptions, as $H = 1 - [\rho]_{OL}^{AT}/[\rho]_{BL}^{AT}$ and the fraction transferred from liver to the blood of such testosterone $[\rho]_{OB}^{AT} = [\rho]_{OL}^{AT}/[\rho]_{BL}^{AT}$. However, the contribution to blood testosterone from dehydroepiandrosterone will be $P^{D} \times [\rho]_{OL}^{AT} \times [\rho]_{BL}^{AT} = P^{D} \times [\rho]_{OL}^{AT} \times ([\rho]_{OL}^{AT}/[\rho]_{BL}^{AT}) = [\rho]_{OL}^{AT}$ in the numerator and $[\rho]_{OL}^{AT}$ in the denominator will be affected by the failure of assumption 3 to the same extent, and hence any correction factor due to this will cancel. As 1 and 2 are reasonable assumptions, the major uncertainties in the treatment of contributions from dehydroepiandrosterone will therefore be assumption 4 and that the hepatic extraction and conversion of testosterone made from androstenedione, which has itself been formed from dehydroepiandrosterone in the liver, are the same as testosterone made hepatically from androstenedione entering the liver after being administered orally or intravenously. Comparison of the maximal hepatic extractions of testosterone from the clearance rate values (60%) and from oral administration of androstenedione (>98%) does suggest that testosterone made hepatically from andros-
Discussion

Since in normal man the hepatic plasma flow is 1,600 L per day (19), metabolic clearance rates of steroids that exceed this value indicate significant extrahepatic metabolism even if the hepatic extraction is 100%. The finding that the clearance rate of androstenedione is 2,330 L per day indicates that at least one-third of the total metabolism must be extrahepatic. If the hepatic extraction were less than 100%, the proportion of extrahepatic metabolism would be even greater. It seems unlikely that this amount of extrahepatic clearance could be due to conversion of androstenedione to testosterone, as only 6% ([ρ]BBAT) of intravenous infused androstenedione is metabolized in this manner. It seems more likely that the 5α- and 5β-androsterones or other metabolites or both are formed from androstenedione both in the liver and extrahepatically.

The metabolic clearance rate of testosterone as determined by a single injection procedure has been reported as 965 L per day by Horton, Shin-sako, and Forsham (3) with similar values by Hudson, Coglan, Dulmanis, and Wintour (7). These estimates are not significantly different from those obtained by a continuous infusion procedure in this study. The infusion method is, however, in many respects technically simpler to perform, and it allows for easier testing of attainment of equilibrium and calculation of results and errors. As has been previously discussed (3), this MCR value of testosterone indicates a maximal hepatic extraction of about 60% for this steroid.

Androstenedione is metabolized differently from preformed testosterone entering the liver although the validity of assumption 4 is involved in this conclusion. However, Migeon (18) has obtained a value of 50% for the splanchnic extraction of testosterone entering the liver by direct analysis of hepatic venous blood. Also, urinary data indicate that the metabolism of androstenedione depends on whether it is secreted or formed from dehydroepiandrosterone (8). Nevertheless, the vital assumption made in the calculation of the contribution from dehydroepiandrosterone is that the metabolism of testosterone formed from androstenedione does not depend on the source of the androstenedione. Although this assumption has not been rigorously tested in the present studies because of the difficulties in devising a meaningful experiment, it appears to be more likely to be true than that the metabolism of a steroid depends on whether it is preformed or converted at the site of the metabolism from a precursor.

when administered intravenously, which suggests that it may be bound to some extent to plasma proteins other than albumin (4).

The production rates of a steroid in plasma (blood production rate) can be calculated as the product of its metabolic clearance rate and mean plasma concentration (5). In the case of interconverting compounds, the blood production rate is the sum of steroid directly secreted plus that synthesized peripherally that enters the blood (4, 5). The blood production rates of androstenedione calculated from the data obtained in these studies are 3.4 and 1.4 mg per day in the female and male, respectively. Vande Wiele, MacDonald, Gurpide, and Lieberman (2) calculated urinary production rates of androstenedione in both sexes as about 10 mg per day by measuring the specific activities of urinary 5α- and 5β-androsterones. This is another example of discrepancies (5) in the estimates of urinary and blood production rates. These discrepancies could be due to production of androstenedione from precursors such as testosterone and dehydroepiandrosterone that do not enter the general circulation, perhaps because of appreciable hepatic extraction, but do lead to formation of 5α- and 5β-androsterone. The larger discrepancy in the male compared with the female could be due to a secretion of more precursor as testosterone and hence production of androstenedione by conversion relative to the amount of androstenedione that enters the blood directly by secretion. Similarly, the blood production rates of testosterone are 7 and 0.34 mg per day in the male and female, whereas the corresponding urinary production rates calculated from the specific activity of urinary testosterone glucuronide are 7 and 1.8 mg per day (3). The lack of discrepancy in the urinary and blood production rates of testosterone in the male is due to the relatively low blood production rate (1.4 mg per day) of the major precursor, androstenedione, compared with the blood production rate of testosterone (7 mg per day). However, in the female the blood production rates of androstenedione and testosterone are 3.4 and 0.34 mg per day, respectively. About 40% of the blood androstenedione (i.e., 1.4 mg per day) would be converted to testosterone, which gives rise to urinary testosterone glucuronide according to several groups of investigators (2, 7, 9, 10, 20), but only 6%, [ρ]BBAT, or 0.2 mg
per day would contribute to the blood production of testosterone. These new data on androstenedione therefore support previous calculations regarding testosterone (10) and the general conclusion (3, 5, 6, 9, 10) that although urinary production rates may give estimates of the total synthesis of steroid in the body, they do not always give the amount of steroid entering the general circulation.

Consideration of the concentration of testosterone in female plasma (0.035 μg per 100 ml) and the ratio of radioactivity measured as androstenedione to testosterone \((Z^A/Z^T = 0.028)\) after intravenous administration of labeled testosterone shows that a negligible proportion of the total plasma concentration of androstenedione (0.14 μg per 100 ml) is due to plasma testosterone. However, as the ratio of radioactivity measured as testosterone to androstenedione \((x^T/x^A)\) after intravenous infusion of androstenedione is 0.14, then 0.02 of 0.035 μg per 100 ml or 60% of the plasma testosterone is converted from plasma androstenedione. Forty per cent of the plasma testosterone in the female must, therefore, come from sources that do not contribute to plasma androstenedione. Similar calculations can be made with blood production rates and transfer constants \([\rho]\) values) with identical conclusions regarding the proportion of product made from precursor in the plasma. As the interconversion rates seem to be the same in both sexes, it can also be calculated that in the male a negligible amount of plasma testosterone comes from plasma androstenedione but 0.022 of a total of 0.060 μg per 100 ml or 36% of the plasma androstenedione is converted from plasma testosterone (Figure 1).

The fraction of precursor converted to product in plasma (the \([\rho]\) values) is similar for androstenedione to testosterone \([\rho]_{BBAT} = 5.9\%\) and for the reverse process \([\rho]_{BBTA} = 6.6\%). When labeled androstenedione is given intravenously, the steroid is available for both splanchnic and extrasplanchnic conversion although some of the testosterone produced may not enter the general circulation. Therefore, the determination of \([\rho]_{BBAT}\) as 5.9% by intravenous infusion gives no information as to the site of the conversion. When labeled androstenedione is given by oral infusion, however, only 6.3% of this precursor enters the general circulation as androstenedione itself, and the possibility of radioactivity as testosterone in plasma being formed \((< 6.3 \times [\rho]_{BBAT})\) extrahepatically by conversion from androstenedione is considerably reduced \((< 6.3 \times 5.9 < 0.37\%\)). Actually, 1.8% of the orally infused androstenedione enters the plasma as testosterone compared with 5.9% after intravenous androstenedione. If, therefore, it could be assumed that orally infused androstenedione enters and is converted to testosterone in the liver as effectively as intravenously administered androstenedione, at least 70% \([(5.9 - 1.8)/5.9]\) of the plasma testosterone converted from plasma androstenedione is made extrasplanchnically. This assumption seems reasonable, as 89% of orally administered androstenedione is converted to urinary testosterone glucuronide compared with intravenously administered testosterone, whereas the corresponding value after intravenous injection of both androstenedione and testosterone is about 40% (2, 7, 9, 10, 20).

Little testosterone enters the general circulation after oral administration of androstenedione, indicating that urinary testosterone glucuronide is formed in the splanchnic circulation. The higher conversion of androstenedione to testosterone when given orally compared with intravenous administration is reasonable in view of the high recovery of radioactivity in urine after oral androstenedione, indicating efficient absorption of this steroid by the intestinal tract, and the evidence previously discussed that androstenedione is appreciably metabolized extrahepatically to compounds other than testosterone when given intravenously. As a small but significant proportion of the testosterone in plasma after oral administration of androstenedione (0.37 out of 1.8%) is converted from plasma androstenedione and more testosterone is formed in the liver after oral than after intravenous infusion of androstenedione, it seems reasonable to conclude that a negligible proportion of the testosterone in plasma from intravenous androstenedione is made originally in the splanchnic circulation and that the process largely occurs in extrasplanchnic tissues. The exact anatomical sites of this conversion are still unknown. It is unlikely to be in blood itself according to the study previously described here. Thomas and Dorfman have reported that this conversion may occur in the muscle of the rat (21).

A \([\rho]_{BBAT}\) value can also be calculated from the
data of Korenman and Lipsett, who measured the 
$^{14}\text{H}/^{14}\text{C}$ ratio of the testosterone in plasma and urin-
ary testosterone glucuronide after a single in-
jection of androstenedione-$^2\text{H}$ and testosterone-$^{14}\text{C}$
(10). The two values, where this can be calcu-
lated, are 8.0 and 5.8%, which are in reasonable
agreement with our mean value of 5.9. However,
Korenman and Lipsett then assumed that extras-
planchnic conversion of androstenedione to testos-
erone was negligible and that the testosterone
converted from androstenedione appearing in the
plasma came from the liver. The splanchnic ex-
traction of the testosterone formed in the liver
(the per cent testosterone formed there that is
irreversibly metabolized) could then be calculated
as 75 and 83% in the two experiments. Koren-
man and Lipsett clearly stated the assumption in-
volved in this calculation, but the only relevant
experimental evidence presented was the lack of
rapid conversion in vitro in blood. We have con-
firmed this observation, but this does not elimi-
ate the possibility of conversion of androstenedione
to testosterone in extraplanchnic tissue. The ex-
periments described here in which androstenedione
was given orally suggest a much higher splanchnic
extraction of testosterone formed in the liver from
androstenedione and formation of plasma testos-
erone mainly by extraplanchnic conversion of
androstenedione. This calculation does not de-
pend on any assumption involving extraplanchnic conversion but instead that the conversion of
androstenedione to testosterone is negligible be-
fore the radioactive steroid enters the hepatic por-
tal circulation. This is apart from the other as-
sumptions and considerations detailed in foot-
note 5, which are also common to the conclusions
of Korenman and Lipsett. If either the orally ad-
ministered androstenedione-$^{14}\text{C}$ or formed testos-
erone was metabolized to compounds other than
testosterone glucuronide before entering the portal
circulation, this would not affect the validity of
the calculations as this is allowed for in the yield
of $^{14}\text{C}$-labeled urinary testosterone glucuronide.
If the testosterone formed in the gut were not
metabolized before entering the portal circula-
tion, this would affect the calculation and give rise
to an overestimate in the value for the splanchnic
extraction. However, from the MCR value of
testosterone, as previously discussed, the maxi-
mal splanchnic extraction of testosterone entering
the liver would be about 60%. Recently, Migeon
(18) has measured the extraction of testosterone
presented to the liver by direct hepatic venous
blood analysis and found it to be about 50% (al-
though the hepatic extraction of androstenedione
measured at the same time was nearly 100%).
Thus if appreciable amounts of testosterone formed
from the oral androstenedione entered the portal
circulation, much larger amounts than were meas-
ured would be expected to enter the peripheral
circulation. The remaining possibility to be con-
sidered is that little testosterone enters the portal
circulation but that appreciable amounts of testos-
erone and testosterone glucuronide were formed
in the gut from the oral androstenedione. This
possibility would mean that the gut is highly effi-
cient in metabolizing testosterone and that appreci-
able amounts of testosterone glucuronide are also
formed there. This possibility has not been dis-
proved experimentally in the present studies, but
it seems much less likely then that the assumption
that extrasplanchnic conversion of androstenedione
to testosterone is negligible, which gives rise to
the lower estimate of splanchnic extraction.

Forty per cent (0.04 µg per 100 ml or 0.14 mg
per day) of the plasma testosterone in the female
is not formed from plasma androstenedione. This
proportion could be due to testosterone 1) secreted
directly into the general circulation or 2) formed
from a source of androstenedione that does not
enter the peripheral blood or 3) produced by a
chemical pathway not including androstenedione as
an intermediate. As regards 3, that this could
be due to testosterone formed by hydrolysis
from secreted testosterone glucuronide seems un-
likely from the available evidence. There is a
possibility, however, that other pathways such as
through secretion of Δ$^\text{A}$-androstenediol, which
could be converted to testosterone without going
through androstenedione, could make a contri-
bution that would lead to an overestimate of the
secretion ratio. As regards the second possibility,
androstenedione formed from dehydroepiandro-
terone in the liver may not enter the general cir-
culation but may form testosterone hepatically; this
product may contribute significantly to blood tes-
tosterone. The oral experiments indicate that the
hepatic extraction of testosterone formed from
oral androstenedione is at least 98%. Data in the
literature indicate that 4 to 10% of intravenously
administered dehydroepiandrosterone is converted
to testosterone glucuronide compared to the simi-
lar conversion of intravenous testosterone (2, 9),
indicating that 4 to 10% of the production rate of
dehydroepiandrosterone is converted to testoster-
one heptatically. Production rates of dehydroepi-
androsterone have been reported as about 10 mg
per day in both sexes (2). This would indicate a
production rate of testosterone from dehydro-
epiandrosterone in the liver of about 0.6 mg per
day of which a maximum of 0.01 mg per day would
enter the general circulation. These calculations
therefore show that this source of androstenedione
(or other pathways from dehydroepiandrosterone
leading to production of testosterone in the liver)
is unlikely to give rise to a significant amount of
plasma testosterone (< 0.01 of 0.34 mg per day)
even in the female.8 This conclusion is supported
by the minimal (< 20%) elevation of plasma
testosterone resulting from prolonged administra-
tion of ACTH despite marked increases in total
urinary 17-ketosteroids (22). This result also
indicates that extrasplanchnic conversion of de-
hydroepiandrosterone, whatever the chemical path-
way, e.g., through androstenedione or Δ5-andros-
tenediol, is not a major factor in contributing to
blood testosterone.

Therefore, it can be concluded that secretion of
testosterone (0.14 of 0.34 total mg per day) is
the probable major source of plasma testosterone
not derived from plasma androstenedione (0.20
of 0.34 total mg per day), although theoretically
some of this 0.14 mg per day could be due to con-
version from precursors such as secreted Δ5-
androstenediol.

All the plasma androstenedione in the female
originates from a source other than plasma testos-
terone. A conclusion that this must be due to se-
cretion of androstenedione seems likely, but must
be less certain than the conclusion that the source of
testosterone in the female is not from plasma
androstenedione. This is because although the
high clearance rate of androstenedione and the
low [\(\rho\)]BBTA value [taken together with urinary
data indicating that testosterone is very efficiently
converted to androstenedione heptatically (2, 20)]
also suggest nearly complete extraction of andros-
tenedione made from a precursor, testosterone, the
metabolism of other precursors such as dehydro-
epiandrosterone preferably after oral and intrave-
nous infusion has not yet been studied. As 60%
of plasma testosterone is made from plasma an-
drostenedione, it seems that the ACTH experi-
ments also indicate that dehydroepiandrosterone
does not contribute significantly to plasma an-
drostenedione. Also, it has been found that plasma
androstenedione is not raised in female subjects
during acute surgery (23). Nevertheless, the
possible contributions of other precursors such as
17-hydroxyprogesterone although unlikely to
be significant have not been thoroughly considered.
Therefore, although it can be concluded that the
secretion of androstenedione in the female is prob-
ably about 3.4 mg per day, or nearly all the blood
production rates, this estimate must be viewed
with some reservations. The estimate of the se-
cretion of testosterone is more certain, as the ap-
propriate major immediate precursor, androstene-
dione, whether it is secreted or produced from
dehydroepiandrosterone or other compounds such
as 17-hydroxyprogesterone, has been considered
more rigorously in the calculations. Nevertheless,
it seems likely that the blood production rate of
androstenedione in the female is due to secreted
androstenedione, and if this is so then this com-
pound can be considered the major secreted an-
drogen in young adults of this sex insofar as, even
if it has no intrinsic biological activity of its own,
it gives rise to most of the circulating testosterone,
the most active naturally occurring androgen
known. The reason, if any, for secretion or pro-
duction of a precursor rather than the final hor-
mon e in the female but not in the male is an in-
triguing question that remains to be investigated.

The values of < 1 µg androstenedione per 100
ml plasma from normal female ovarian venous
blood (24), which have been confirmed by the
thiosemicarbazide-4S method (23), and about 10
µg androstenedione per 100 ml plasma in normal
female adrenal venous blood (25, 26) would sug-
gest that the adrenal and not the ovary is the ma-
jor source of secreted androstenedione in the fe-
male if the blood flows through the two endocrine
organs are comparable. However, Wieland and
his colleagues (25) conclude that this adrenal an-
drostenedione is under ACTH control, whereas
as blood testosterone is not increased by ACTH,
our evidence would suggest that secreted andros-
tenedione is also not affected by this pituitary hor-
mine in the female. Further studies on the source
of androstenedione are needed to explain this discrepancy.

Summary

The androstenedione metabolic clearance rate, production rate in blood, and conversion rate to blood testosterone have been determined by analysis of plasma concentration of steroid by a double isotope derivative technique and by measurement of radioactivity as precursor and product steroid in plasma after introduction of labeled precursors into the general circulation. The metabolic clearance rate of androstenedione is 2,330 ± 107 (SE) L per day indicating considerable extrahepatic metabolism, whereas the metabolic clearance rate of testosterone [980 ± 54 (SE) L per day] suggests a hepatic extraction of secreted testosterone considerably less than 100%. The blood production rate of androstenedione is 3.4 mg per day in the female and 1.4 mg per day in the male compared with testosterone blood production rates of 0.34 and 7 mg per day, respectively. Consideration of the production rates in plasma of testosterone and androstenedione offers an explanation of the agreement in production rates in blood or urine of testosterone in males, and of the considerable discrepancy in the corresponding estimates in females due to the marked relative predominance of androstenedione as precursor in the blood of females. The determination of conversion rates in blood indicates that essentially no androstenedione arises from blood testosterone in the female; however, 60% of plasma testosterone results from the peripheral conversion of plasma androstenedione. The remaining 40% is probably due to secretion of testosterone or, less likely, conversion from precursors such as secreted Δ4-androstenediol. Finally, the very low radioactivity as testosterone in plasma after the oral administration of labeled androstenedione suggests that the primary site of the conversion of blood androstenedione to blood testosterone is extrasplanchic.

The determination of production and secretion rates of these interconverting hormones by analysis in blood may give more precise and relevant results than urinary or combined blood and urinary methods previously used for such calculations.

Acknowledgments

We are grateful for permission given by Dr. Charles Lloyd to quote some unpublished observations regarding the effect of ACTH on testosterone in plasma. Also we benefited by discussions with Drs. J. Coghlan, B. Hudson, and E. Baulieu.

References

ANDROSTENEDIONE PRODUCTION AND CONVERSION RATES


22. Lloyd, C. W. Personal communication.


ANNOUNCEMENT OF MEETINGS

The American Federation for Clinical Research will hold its Twenty-third Annual Meeting in Atlantic City, N. J., in the Pennsylvania Room, Haddon Hall, on Sunday, May 1, 1966, at 9:00 a.m. Joint sectional meetings with the American Society for Clinical Investigation will be held on Sunday afternoon at Chalfonte-Haddon Hall, and additional meetings sponsored by The American Federation for Clinical Research will be held on Sunday evening.

The American Society for Clinical Investigation, Inc., will hold its Fifty-eighth Annual Meeting in Atlantic City, N. J., on Monday, May 2, at 9:00 a.m., in the Pennsylvania Room, Haddon Hall, and will join The American Federation for Clinical Research in simultaneous sectional meetings on Sunday afternoon, May 1, at Chalfonte-Haddon Hall.

The Association of American Physicians will hold its Seventy-ninth Annual Meeting in Atlantic City, N. J., in the Pennsylvania Room, Haddon Hall, on Tuesday, May 3, at 9:30 a.m., and in the Carolina Room, Chalfonte, on Wednesday, May 4, at 9:30 a.m.